Wall Street analysts expect Alliqua Biomedical Inc (NASDAQ:ALQA) to post ($0.02) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Alliqua Biomedical’s earnings. Alliqua Biomedical reported earnings of ($0.79) per share during the same quarter last year, which would suggest a positive year over year growth rate of 97.5%. The business is scheduled to issue its next earnings results on Thursday, November 8th.
On average, analysts expect that Alliqua Biomedical will report full year earnings of $5.14 per share for the current financial year. For the next financial year, analysts forecast that the firm will report earnings of ($0.09) per share. Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that follow Alliqua Biomedical.
Alliqua Biomedical (NASDAQ:ALQA) last posted its quarterly earnings data on Friday, August 10th. The company reported ($0.66) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.64). Alliqua Biomedical had a negative net margin of 99.08% and a negative return on equity of 169.35%. The company had revenue of $0.86 million for the quarter.
Shares of NASDAQ ALQA traded down $0.03 on Friday, reaching $2.37. 281 shares of the company traded hands, compared to its average volume of 17,640. Alliqua Biomedical has a fifty-two week low of $1.58 and a fifty-two week high of $4.50. The company has a market cap of $11.56 million, a P/E ratio of -0.36 and a beta of 1.12.
Alliqua Biomedical Company Profile
Alliqua BioMedical, Inc, a regenerative technologies company, commercializes regenerative medical products that assist the body in the repair or replacement of soft tissue. The company markets MIST Ultrasound Healing Therapy, a painless noncontact low-frequency ultrasound to promote healing; and Biovance Amniotic Membrane Allograft and Interfyl Human Connective Tissue Matrix, which are human biologic regenerative technologies.
Featured Article: Market Capitalization and Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alliqua Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.